tradingkey.logo

Beta Bionics Inc

BBNX
View Detailed Chart
13.080USD
-0.160-1.21%
Close 02/06, 16:00ETQuotes delayed by 15 min
575.41MMarket Cap
LossP/E TTM

Beta Bionics Inc

13.080
-0.160-1.21%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.21%

5 Days

-5.42%

1 Month

-58.34%

6 Months

-13.95%

Year to Date

-57.07%

1 Year

-44.27%

View Detailed Chart

TradingKey Stock Score of Beta Bionics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Beta Bionics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.82.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beta Bionics Inc's Score

Industry at a Glance

Industry Ranking
55 / 205
Overall Ranking
158 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Beta Bionics Inc Highlights

StrengthsRisks
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36282.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.12M.
Overvalued
The company’s latest PE is -6.73, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 48.60M shares, increasing 0.09% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.22M shares of this stock.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
28.818
Target Price
+117.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Beta Bionics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Beta Bionics Inc Info

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Ticker SymbolBBNX
CompanyBeta Bionics Inc
CEOSaint (Sean)
Websitehttps://www.betabionics.com
KeyAI